ER PROTAC Composition for Selective Receptor Degradation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing estrogen receptor (ER) targeted therapies face challenges with limited molecular membrane permeability, inadequate potency, and drug resistance, necessitating a more selective and potent approach for ER degradation.
Innovation Solution
Development of estrogen receptor proteolysis targeting chimera (PROTAC) compounds that utilize a cereblon E3 ubiquitin ligase binding moiety and a specific estrogen receptor binding moiety connected by a linker, facilitating the degradation of ER proteins through the proteasome system.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional small-molecule inhibitors are used to target estrogen receptor, then they can inhibit the receptor activity, but they exhibit drug-resistant effects due to target protein variation and have limited potency
Solution Approach 1:
Instead of inhibiting the estrogen receptor's function through binding (traditional approach), the PROTAC compound induces degradation of the target protein by recruiting E3 ubiquitin ligase to ubiquitinate and degrade the receptor via the proteasome system, fundamentally inverting the mechanism from functional inhibition to protein destruction
Solution Approach 2:
The PROTAC compound acts as a bifunctional intermediary molecule that simultaneously binds to the estrogen receptor (via PTM) and recruits E3 ubiquitin ligase (via CLM), facilitating the ubiquitination process and enabling targeted protein degradation through the proteasome system
2Power
If PROTAC compounds are designed to achieve irreversible degradation of target proteins, then they can overcome drug resistance and enhance potency, but they require complex bifunctional molecular structures with linker units
Solution Approach 1:
The PROTAC compound is segmented into distinct functional modules: an estrogen receptor binding moiety (PTM), a linker unit (L), and a cereblon E3 ligase binding moiety (CLM). This segmentation allows each component to perform its specific function while maintaining overall molecular stability and activity
Solution Approach 2:
The PROTAC compound serves multiple functions simultaneously: it binds to the estrogen receptor, recruits E3 ubiquitin ligase, facilitates ubiquitination, and directs target protein to the proteasome for degradation, making it a multi-functional molecular entity that addresses multiple therapeutic needs
3Reliability
If PROTAC compounds use cereblon E3 ligase binding moieties for target protein degradation, then they achieve micromolar-affinity binding and improved selectivity, but they face challenges with molecular membrane permeability
Solution Approach 1:
The patent optimizes molecular parameters including the linker unit length and composition, the size and structure of binding moieties, and overall molecular weight to balance membrane permeability with binding affinity and selectivity for the cereblon E3 ligase complex
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The PROTAC compounds achieve irreversible and selective degradation of ER proteins, overcoming drug resistance and enhancing pharmacodynamic efficacy.
Implementation Method 1
The ligand of E3 ubiquitin ligase recruits the E3 ubiquitin ligase to the vicinity of the target protein, which in turn ubiquitinates and labels the target protein
Implementation Method 2
The labeled target protein will be degraded by the proteasome system in vivo
Data Source
AI summary
Provided are a novel estrogen receptor proteolysis targeting chimera compound and a use thereof in medicine. The compound provided by the present invention can be used as an estrogen receptor degrader for treating estrogen-dependent diseases.